title: A Nonhormonal Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.
abstract: It is estimated that up to 80% of women experience symptoms related to declining estrogen levels that occur with menopause. The most common bothersome symptoms reported by women during and after this transition are vasomotor symptoms, which can include hot flashes, flushing, night sweats, and sleep disturbances. These symptoms are the most common reason women seek care during menopause. Until recently, the mainstay of treatment and symptom relief has been estrogen supplementation. In 2013, the U.S. Food and Drug Administration approved paroxetine, a low-dose selective serotonin reuptake inhibitor, as the first nonhormonal treatment for moderate to severe vasomotor symptoms of menopause. This article provides an overview of the use of paroxetine to treat vasomotor symptoms of menopause, including potential adverse reactions, special considerations for use, and implications for nursing practice.
authors.forename: Heidi Collins
authors.initials: HC
authors.lastname: Fantasia
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000328:Adult; D005260:Female; D019584:Hot Flashes / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008019:Life Style; D008593:Menopause / Q000502:physiology*; D008875:Middle Aged; D017374:Paroxetine / Q000627:therapeutic use; D010353:Patient Education as Topic; D008517:Phytotherapy / Q000379:methods*; D014652:Vascular Diseases / Q000209:etiology* / Q000517:prevention & control
chemical_list: D000316:Adrenergic alpha-Agonists; D017374:Paroxetine
keywords: hot flash; menopause; paroxetine; vasomotor symptoms